Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$88.76 USD

88.76
5,165,991

-0.24 (-0.27%)

Updated Oct 28, 2024 04:00 PM ET

After-Market: $88.76 0.00 (0.00%) 6:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Pluristem Up on Cell Therapy Treatment of Coronavirus Patient

Pluristem (PSTI) gains on the treatment of first patient suffering from COVID-19 complications with its cell therapy.

Ekta Bagri headshot

Will Stem Cell Therapies Aid in Fight Against Coronavirus?

With the coronavirus outbreak gaining steam worldwide, pharma/biotech companies are evaluating every possible therapy to combat the spread.

Gilead Reports Promising Data on Experimental Coronavirus Drug

Gilead (GILD) reports encouraging data on investigational antiviral, remdesivir, in patients hospitalized with COVID-19.

Neena Mishra headshot

Coronavirus Testing, Vaccines & Treatments: What You Should Know

We discuss latest developments in tests, vaccines and therapies for COVID-19.

Biotech Stock Roundup: AMGN & INCY Focus on Coronavirus Treatments, & More

The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.

Sweta Jaiswal, FRM headshot

Biotech Stocks, ETFs to Gain on COVID-19 Vaccine & Drug Progress

The race to introduce a vaccine and drug for COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.

Gilead Partners Second Genome, Boosts Coronavirus Drug Production

Gilead (GILD) collaborates with Second Genome for inflammatory bowel disease treatments. The company also plans to ramp up production of remdesivir for coronavirus treatment.

Kinjel Shah headshot

Is Pharma the Sector to Bet on in 2020? 2 Big Stocks to Buy

Here we have highlighted two big pharma stocks that may prove to be good buys. Both these stocks carry a Zacks Rank #1 (Strong Buy) and have seen their share price rise this year.

Sanghamitra Saha headshot

These Medical ETFs & Stocks Deserve a Salute on Health Day

The World Health Day of 2020 puts these medical companies and the related stocks and ETFs in focus.

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $77.73, moving -0.61% from the previous trading session.

Novo Nordisk's Rybelsus Gets EU Nod for Type II Diabetes

Novo Nordisk (NVO) gains the EU approval for Rybelsus to address adult patients with insufficiently-controlled type II diabetes for improving glycemic control as an adjunct to diet and exercise.

Regeneron-Sanofi's Dupixent Data Positive in Atopic Dermatitis

Regeneron (REGN) and Sanofi announce positive detailed data on Dupixent in children aged 6-11 years with uncontrolled severe atopic dermatitis.

Moderna Stock Surges 78% YTD on Coronavirus Vaccine Progress

Moderna (MRNA) is making significant progress in development of coronavirus vaccine. It is actively preparing for a potential phase II study.

Sanghamitra Saha headshot

Top Leveraged ETFs of Last Week

These leveraged ETFs won last week despite a broader market bloodbath.

Kinjel Shah headshot

Pharma Coronavirus Efforts Continue, Amgen & Incyte Join In

Amgen (AMGN) signs a deal with Adaptive Biotechnologies to discover antibodies to prevent/treat COVID-19. Incyte/Novartis (NVS) plan to initiate study on Jakafi for COVID-19- associated cytokine storm.

Incyte to Evaluate Lead Drug Jakafi for COVID-19 Infection

Incyte (INCY) plans to work with the FDA for evaluating Jakafi in patients with COVID-19-associated cytokine storm.

Benjamin Rains headshot

Bull of the Day: Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals, Inc. (REGN) shares have surged 30% in 2020 as investors clamor for stocks that appear immune to the coronavirus economic downturn...

Neena Mishra headshot

Can Buffett-Style Investing Succeed Today? Stocks & ETFs to Consider

Companies with strong competitive advantage are expected to succeed in this challenging environment.

Mark Vickery headshot

No Foolin': ADP Report Better than Expected

The ADP headline number came out much better than expected at -27K private sector payroll totals; expectations were for -125K.

ADP Report Better than Expected

ADP Report Better than Expected

Gilead Sciences (GILD) Stock Moves -1.54%: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $74.76, marking a -1.54% move from the previous day.

The Zacks Analyst Blog Highlights: Novartis, Teva, Gilead and AbbVie

The Zacks Analyst Blog Highlights: Novartis, Teva, Gilead and AbbVie

Gilead Expands Access to Experimental Coronavirus Treatment

Gilead (GILD) looks to expand access programs to accelerate access to remdesivir for COVID-19 patients.

Sejuti Banerjea headshot

COVID-19 Claiming Lives But Therapeutics Could Be on the Way

The WHO's Solidarity testing project could be good news for the world.

Sanofi Begins Kevzara Study for Severe Coronavirus Infection

Sanofi (SNY) begins treatment in a second phase II/III study evaluating its rheumatoid arthritis drug Kevzara to treat patients with severe COVID-19 outside the United States.